Synmosa (健喬) announced an exclusive licensing agreement with Zai Lab (再鼎醫藥) to commercialize six global innovative therapies in Taiwan. Zai Lab is a NASDAQ and HKEX-listed biopharmaceutical leader. This partnership aligns with Synmosa's "International Licensing, Strategic Alliance, and Accelerated Local Implementation" strategy.
The Six Innovative Therapies:
- Optune (Tumor Treating Fields): A world-first, non-invasive physical therapy for Glioblastoma (GBM). It uses low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell mitosis. (Approved in Taiwan).
- Qinlock (Ripretinib): A novel switch-control tyrosine kinase inhibitor for Gastrointestinal Stromal Tumors (GIST). It is the only option for third-line patients who have relapsed. (Approved in Taiwan).
- Augtyro (Repotrectinib): A next-generation TKI for ROS1-positive NSCLC and NTRK-positive solid tumors. It features superior CNS penetration to treat brain metastases and remains active against resistance mutations like G2032R. (Approved in Taiwan).
- Tivdak (Tisotumab vedotin-tftv): The first US FDA-approved Antibody-Drug Conjugate (ADC) targeting Tissue Factor (TF) for Cervical Cancer.
- Vyvgart (Efgartigimod alfa): A first-in-class FcRn inhibitor that selectively reduces pathogenic IgG, used for Generalized Myasthenia Gravis (gMG).
- Cobenfy (Xanomeline/Trospium): The first M1/M4 muscarinic receptor agonist for Schizophrenia. It avoids traditional dopamine-blocking side effects, addressing both positive and negative symptoms while improving compliance.
Chairman Lin Chih-hui emphasized that this collaboration marks Synmosa's transformation from a local manufacturer to a high-end innovator, addressing significant unmet needs for over 100,000 patients in Taiwan.
Resource: 健喬結盟再鼎台灣醫藥 取得六項創新療法台灣市場代理與商業化權利
